3.225
price down icon10.42%   -0.375
after-market  After Hours:  3.2016  -0.0234   -0.73%
loading
Heron Therapeutics Inc stock is currently priced at $3.225, with a 24-hour trading volume of 2.86M. It has seen a -10.42% decreased in the last 24 hours and a +0.78% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.62 pivot point. If it approaches the $3.39 support level, significant changes may occur.
Previous Close:
$3.60
Open:
$3.6
24h Volume:
2.86M
Market Cap:
$485.86M
Revenue:
$127.04M
Net Income/Loss:
$-110.56M
P/E Ratio:
-2.7564
EPS:
-1.17
Net Cash Flow:
$-60.33M
1W Performance:
-12.60%
1M Performance:
+0.78%
6M Performance:
+78.18%
1Y Performance:
+166.53%
1D Range:
Value
$3.21
$3.605
52W Range:
Value
$0.50
$3.93

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name
Name
Heron Therapeutics Inc
Name
Phone
858-251-4400
Name
Address
4242 Campus Point Court, Suite 200, San Diego, CA
Name
Employee
145
Name
Twitter
Name
Next Earnings Date
2024-06-13
Name
Latest SEC Filings
Name
HRTX's Discussions on Twitter

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-27-20 Initiated Guggenheim Buy
Feb-20-20 Reiterated Needham Buy
Jan-16-19 Reiterated Needham Buy
Apr-05-18 Initiated Evercore ISI Outperform
Mar-19-18 Reiterated Mizuho Buy
Mar-01-18 Reiterated Needham Buy
Jan-03-18 Initiated Leerink Partners Outperform
Sep-27-17 Initiated Northland Capital Outperform
Feb-27-17 Initiated Needham Buy
Oct-26-16 Initiated Aegis Capital Buy
Sep-06-16 Resumed Lake Street Buy
May-03-16 Initiated Cantor Fitzgerald Buy
Dec-10-15 Initiated Lake Street Buy
Sep-23-15 Reiterated Leerink Partners Outperform
Sep-02-15 Initiated BofA/Merrill Buy
Aug-03-15 Reiterated Brean Capital Buy
Jun-30-15 Reiterated JMP Securities Mkt Outperform
Jun-19-15 Reiterated Leerink Partners Outperform
Aug-07-14 Initiated Noble Financial Buy
View All

Heron Therapeutics Inc Stock (HRTX) Financials Data

Heron Therapeutics Inc (HRTX) Revenue 2024

HRTX reported a revenue (TTM) of $127.04 million for the quarter ending December 31, 2023, a +17.99% rise year-over-year.
loading

Heron Therapeutics Inc (HRTX) Net Income 2024

HRTX net income (TTM) was -$110.56 million for the quarter ending December 31, 2023, a +39.26% increase year-over-year.
loading

Heron Therapeutics Inc (HRTX) Cash Flow 2024

HRTX recorded a free cash flow (TTM) of -$60.33 million for the quarter ending December 31, 2023, a +59.44% increase year-over-year.
loading

Heron Therapeutics Inc (HRTX) Earnings per Share 2024

HRTX earnings per share (TTM) was -$0.84 for the quarter ending December 31, 2023, a +51.45% growth year-over-year.
loading
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
$85.02
price up icon 1.81%
$25.78
price down icon 1.57%
$159.38
price down icon 1.97%
$157.30
price down icon 1.93%
$88.44
price down icon 3.95%
$378.30
price down icon 2.25%
Cap:     |  Volume (24h):